Company intelligence
Foundation for Angelman Syndrome Therapeutics (FAST)
About Foundation for Angelman Syndrome Therapeutics (FAST)
The Foundation for Angelman Syndrome Therapeutics (FAST) is the leading patient advocacy organization working to cure Angelman syndrome. As the largest non-governmental funder of Angelman syndrome research in the world, our goal is to drive forward transformative research and development programs as quickly as possible for those living with Angelman syndrome — regardless of age or genotype. At the core of FAST's mission is a commitment to bring scientific and therapeutic advancements from bench side to bedside, as quickly and safely as possible. To do so, FAST funds projects at every step in the trajectory of drug development, and we are as dedicated to nurturing promising ideas at their earliest stages as we are to protecting and advancing those that have already shown value. Apply for a grant today. All grant applications are considered on a rolling basis. We move fast so you can too. Learn More: https://cureangelman.org/apply-for-a-grant
Verified activity
Signals from Foundation for Angelman Syndrome Therapeutics (FAST)
5 published signals
People
Foundation for Angelman Syndrome Therapeutics (FAST) welcomed Roy Phillips, Sara Gainey, and Samantha Eisenhauer as new members of the FAST Action Council
Reported by Foundation for Angelman Syndrome Therapeutics (FAST)
People
Foundation for Angelman Syndrome Therapeutics (FAST) welcomed Beth Phillips-Synk as Chair of the FAST Action Council
Reported by Foundation for Angelman Syndrome Therapeutics (FAST)
Research & Knowledge
Foundation for Angelman Syndrome Therapeutics (FAST) learned that the phase 3 Aspire study for GTX-102 (apazunersen) in Angelman syndrome did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI).
Reported by Foundation for Angelman Syndrome Therapeutics (FAST)
Research & Knowledge
Foundation for Angelman Syndrome Therapeutics (FAST) announced that Ionis shared an update on the design of CHAMPION, their phase 3 clinical trial for ION582 (obudanersen) in people with Angelman syndrome due to UPD or ICD.
Reported by Foundation for Angelman Syndrome Therapeutics (FAST)
Research & Knowledge
Foundation for Angelman Syndrome Therapeutics (FAST) published the Summer 2026 Angelman Syndrome Community Newsletter by Ultragenyx, which includes updates on investigational clinical trials, an Angelman Syndrome Caregiver Leadership Council meeting, and more.
Reported by Foundation for Angelman Syndrome Therapeutics (FAST)